Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743871 · ClinicalTrials.gov registry record · Phase 1
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT02743871 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 97 participants.
The verdict
NCT02743871, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic Dermatitis
Interventions
- BIOLOGICAL PF-06817024
- OTHER Placebo for PF-06817024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2016-04-27 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743871
The ClinicalTrials.gov registry entry for NCT02743871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06817024 is the first listed.
NCT02743871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743871 about?
NCT02743871 is a clinical study titled "Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis". The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with moderate-to-severe Atopic Dermatitis
What is the current status of trial NCT02743871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2016-04-27. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT02743871?
The interventions under investigation include: PF-06817024 (BIOLOGICAL), Placebo for PF-06817024 (OTHER).
Who is sponsoring clinical trial NCT02743871?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.